JP Morgan Chase
RPRX icon

JP Morgan Chase’s Royalty Pharma RPRX Stock Holding History

JP Morgan Chase’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100M Buy
1,755,826
+76,155
+5% +$3.96M 0.01% 1071
2026
Q1 		$77.9M Buy
1,679,671
+161,061
+11% +$7.05M 0.01% 1117
2025
Q4 		$58.7M Sell
1,518,610
-241,010
-14% -$9.19M ﹤0.01% 1258
2025
Q3 		$62.1M Buy
1,759,620
+346,108
+24% +$12.5M ﹤0.01% 1273
2025
Q2 		$50.9M Sell
1,413,512
-21,536
-2% -$714K ﹤0.01% 1317
2025
Q1 		$44.7M Buy
1,435,048
+39,806
+3% +$1.26M ﹤0.01% 1372
2024
Q4 		$35.6M Buy
1,395,242
+105,824
+8% +$2.81M ﹤0.01% 1542
2024
Q3 		$36.5M Sell
1,289,418
-6,449,863
-83% -$179M ﹤0.01% 1543
2024
Q2 		$204M Sell
7,739,281
-255,818
-3% -$7.09M 0.02% 645
2024
Q1 		$243M Sell
7,995,099
-705,220
-8% -$20.8M 0.02% 590
2023
Q4 		$244M Sell
8,700,319
-187,248
-2% -$5.15M 0.02% 560
2023
Q3 		$241M Buy
8,887,567
+151,396
+2% +$4.5M 0.03% 503
2023
Q2 		$269M Buy
8,736,171
+64,608
+0.7% +$2.19M 0.03% 477
2023
Q1 		$312M Buy
8,671,563
+246,816
+3% +$9.15M 0.04% 399
2022
Q4 		$333M Buy
8,424,747
+93,150
+1% +$3.89M 0.04% 372
2022
Q3 		$335M Buy
8,331,597
+683,612
+9% +$29.2M 0.05% 361
2022
Q2 		$322M Buy
7,647,985
+2,088,597
+38% +$85.6M 0.04% 376
2022
Q1 		$217M Buy
5,559,388
+137,185
+3% +$5.39M 0.03% 540
2021
Q4 		$216M Buy
5,422,203
+105,721
+2% +$4.11M 0.03% 539
2021
Q3 		$192M Sell
5,316,482
-1,998,519
-27% -$77.7M 0.02% 589
2021
Q2 		$300M Buy
7,315,001
+1,519,734
+26% +$64.6M 0.04% 481
2021
Q1 		$253M Sell
5,795,267
-285,092
-5% -$13.5M 0.03% 503
2020
Q4 		$304M Buy
6,080,359
+2,329,123
+62% +$98.8M 0.04% 404
2020
Q3 		$158M Buy
3,751,236
+27,312
+0.7% +$1.17M 0.03% 543
2020
Q2 		$181M Buy
+3,723,924
New +$184M 0.03% 473

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's RPRX Position: Q2 2026 in Review

JP Morgan Chase increased its Royalty Pharma (RPRX) stake by 4.5% in Q2 2026, buying an estimated $3.96M and bringing the position to 1,755,826 shares worth $100M. The position accounts for 0.01% of the portfolio, ranked #1071.

JP Morgan Chase first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $335M in Q3 2022. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • JP Morgan Chase held 1,755,826 shares of Royalty Pharma worth $100M as of Q2 2026.
  • JP Morgan Chase bought 76,155 Royalty Pharma shares in Q2 2026, an estimated $3.96M.
  • Royalty Pharma made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1071 holding.
  • JP Morgan Chase first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Royalty Pharma position peaked at $335M in Q3 2022.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.